IRLA Quince Therapeutics | 11/16/2026 | Boost Price Target | $39.80 | $86.00 | Market Outperform | $0.00 00.00% ROI | |
SPRB Spruce Biosciences | 11/12/2026 | Set Price Target | $43.31 | $143.00 | | $0.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 11/4/2026 | Boost Price Target | $86.44 | $166.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 11/4/2026 | Boost Price Target | $87.03 | $167.00 | Market Outperform | $0.00 00.00% ROI | |
DBVT DBV Technologies | 10/29/2026 | Lower Price Target | $10.35 | $47.00 | Market Outperform | $0.00 00.00% ROI | |
IRD Opus Genetics | 10/16/2026 | Reiterated Rating | $4.05 | $17.00 | Market Outperform | $0.00 00.00% ROI | |
BMEA Biomea Fusion | 10/14/2026 | Reiterated Rating | $1.26 | $7.00 | Market Outperform | $0.00 00.00% ROI | |
SGMT Sagimet Biosciences | 10/1/2026 | Lower Price Target | $9.88 | $27.00 | Market Outperform | $0.00 00.00% ROI | |
SPRB Spruce Biosciences | 9/24/2026 | Reiterated Rating | $49.42 | $144.00 | Market Outperform | $0.00 00.00% ROI | |
QNCX Quince Therapeutics | 9/22/2026 | Upgrade | $31.00 | $77.00 | Outperform | $0.00 00.00% ROI | |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
PHVS Pharvaris | 9/9/2026 | Boost Price Target | $37.84 | $79.00 | Market Outperform | $0.00 00.00% ROI | |
GPCR Structure Therapeutics | 9/9/2026 | Reiterated Rating | $40.38 | $110.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 8/27/2026 | Reiterated Rating | $97.55 | $137.00 | Market Outperform | $0.00 00.00% ROI | |
SGMT Sagimet Biosciences | 8/14/2026 | Boost Price Target | $9.28 | $29.00 | Market Outperform | $0.00 00.00% ROI | |
ANNX Annexon | 8/13/2026 | Upgrade | $5.33 | | Market Perform | $0.00 00.00% ROI | |
SPRB Spruce Biosciences | 8/13/2026 | Lower Price Target | $48.38 | $144.00 | Market Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 8/13/2026 | Boost Price Target | $35.58 | $75.00 | Market Outperform | $0.00 00.00% ROI | |
SION Sionna Therapeutics | 8/10/2026 | Downgrade | $4.09 | | Market Perform | $0.00 00.00% ROI | |
GPCR Structure Therapeutics | 8/7/2026 | Lower Price Target | $52.16 | $110.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 8/6/2026 | Lower Price Target | $105.79 | $137.00 | Market Outperform | $0.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 8/5/2026 | Boost Price Target | $108.43 | $160.00 | Market Outperform | $0.00 00.00% ROI | |
ANNX Annexon | 7/21/2026 | Initiated Coverage | $5.57 | $3.00 | Market Underperform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 7/7/2026 | Downgrade | $83.49 | | Hold | $0.00 00.00% ROI | |
DBVT DBV Technologies | 6/30/2026 | Boost Price Target | $16.07 | $55.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 6/15/2026 | Boost Price Target | $102.33 | $146.00 | Market Outperform | $0.00 00.00% ROI | |
IRD Opus Genetics | 6/15/2026 | Reiterated Rating | $4.07 | $11.00 | Market Outperform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 6/11/2026 | Reiterated Rating | $32.99 | $95.00 | Market Outperform | $0.00 00.00% ROI | |
SION Sionna Therapeutics | 5/26/2026 | Reiterated Rating | $41.13 | $63.00 | Market Outperform | $0.00 00.00% ROI | |
SGMT Sagimet Biosciences | 5/19/2026 | Lower Price Target | $6.66 | $12.00 | Market Outperform | $0.00 00.00% ROI | |
SPRB Spruce Biosciences | 5/14/2026 | Lower Price Target | $57.14 | $150.00 | Market Outperform | $0.00 00.00% ROI | |
ALT Altimmune | 5/14/2026 | Lower Price Target | $2.97 | $11.00 | Market Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 5/13/2026 | Lower Price Target | $32.08 | $74.00 | Market Outperform | $0.00 00.00% ROI | |
KLRS Kalaris Therapeutics | 5/13/2026 | Lower Price Target | $4.63 | $25.00 | Market Outperform | $0.00 00.00% ROI | |
IRD Opus Genetics | 5/13/2026 | Lower Price Target | $5.05 | $11.00 | Market Outperform | $0.00 00.00% ROI | |
MBX MBX Biosciences | 5/12/2026 | Boost Price Target | $40.08 | $86.00 | Market Outperform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 5/8/2026 | Lower Price Target | $38.03 | $95.00 | Market Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 5/7/2026 | Boost Price Target | $8.65 | $28.00 | Market Outperform | $0.00 00.00% ROI | |
PTGX Protagonist Therapeutics | 5/6/2026 | Boost Price Target | $101.13 | $137.00 | Market Outperform | $0.00 00.00% ROI | |
BMEA Biomea Fusion | 5/5/2026 | Initiated Coverage | $1.48 | $9.00 | Market Outperform | $0.00 00.00% ROI | |
DBVT DBV Technologies | 5/1/2026 | Boost Price Target | $19.93 | $55.00 | Market Outperform | $0.00 00.00% ROI | |
Worse than socialism (Ad) Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry.
The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization.
Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead. Watch Porter Stansberry's full investment broadcast now |
KALV KalVista Pharmaceuticals | 4/29/2026 | Downgrade | $26.66 | | Hold | $0.00 00.00% ROI | |
IRD Opus Genetics | 4/28/2026 | Initiated Coverage | $5.12 | $12.00 | Market Perform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 4/28/2026 | Boost Price Target | $38.62 | $97.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 4/21/2026 | Reiterated Rating | $94.25 | $132.00 | Market Outperform | $0.00 00.00% ROI | |
DBVT DBV Technologies | 3/27/2026 | Boost Price Target | $20.75 | $47.00 | Market Outperform | $0.00 00.00% ROI | |
KALV KalVista Pharmaceuticals | 3/26/2026 | Lower Price Target | $16.83 | $28.00 | Market Outperform | $0.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 3/17/2026 | Lower Price Target | $90.07 | $152.00 | Market Outperform | $0.00 00.00% ROI | |
SPRB Spruce Biosciences | 3/10/2026 | Lower Price Target | $62.11 | $170.00 | Market Outperform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 3/2/2026 | Lower Price Target | $41.10 | $96.00 | Market Outperform | $0.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 2/27/2026 | Boost Price Target | $98.07 | $176.00 | Market Outperform | $0.00 00.00% ROI | |
GPCR Structure Therapeutics | 2/27/2026 | Lower Price Target | $64.75 | $113.00 | Market Outperform | $0.00 00.00% ROI | |
PTGX Protagonist Therapeutics | 2/26/2026 | Boost Price Target | $86.85 | $112.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 2/26/2026 | Lower Price Target | $92.21 | $132.00 | Market Outperform | $0.00 00.00% ROI | |
SION Sionna Therapeutics | 2/24/2026 | Initiated Coverage | $36.10 | $63.00 | Market Outperform | $0.00 00.00% ROI | |
QNCX Quince Therapeutics | 1/30/2026 | Downgrade | $0.27 | | Market Perform | $0.00 00.00% ROI | |
MDGL Madrigal Pharmaceuticals | 1/20/2026 | Boost Price Target | $501.68 | $745.00 | Market Outperform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 1/8/2026 | Lower Price Target | $53.34 | $105.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 12/19/2025 | Boost Price Target | $70.28 | $140.00 | Market Outperform | $0.00 00.00% ROI | |
DBVT DBV Technologies | 12/17/2025 | Boost Price Target | $17.98 | $45.00 | Market Outperform | $0.00 00.00% ROI | |
GPCR Structure Therapeutics | 12/12/2025 | Boost Price Target | $67.44 | $120.00 | Market Outperform | $0.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 12/12/2025 | Boost Price Target | $117.62 | $167.00 | Market Outperform | $0.00 00.00% ROI | |
SGMT Sagimet Biosciences | 11/14/2025 | Boost Price Target | $7.61 | $35.00 | Market Outperform | $00.00 00.00% ROI | |
SVRA Savara | 11/13/2025 | Lower Price Target | $4.12 | $10.00 | Market Outperform | $0.00 00.00% ROI | |
SPRB Spruce Biosciences | 11/11/2025 | Set Price Target | $115.61 | $259.00 | | $00.00 00.00% ROI | |
SPRB Spruce Biosciences | 11/11/2025 | Boost Price Target | $115.61 | $259.00 | Market Outperform | $00.00 00.00% ROI | |
KALV KalVista Pharmaceuticals | 11/11/2025 | Lower Price Target | $10.89 | $28.00 | Market Outperform | $0.00 00.00% ROI | |
ALT Altimmune | 11/7/2025 | Lower Price Target | $3.94 | $14.00 | Market Outperform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 11/7/2025 | Lower Price Target | $43.49 | $108.00 | Market Outperform | $0.00 00.00% ROI | |
PTGX Protagonist Therapeutics | 11/7/2025 | Boost Price Target | $79.63 | $102.00 | Market Outperform | $000.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 11/5/2025 | Set Price Target | $70.97 | $95.00 | | $00.00 00.00% ROI | |
MDGL Madrigal Pharmaceuticals | 11/5/2025 | Set Price Target | $444.64 | $527.00 | | $000.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 11/5/2025 | Lower Price Target | $6.76 | $25.00 | Market Outperform | $0.00 00.00% ROI | |
MDGL Madrigal Pharmaceuticals | 11/5/2025 | Boost Price Target | $444.64 | $527.00 | Market Outperform | $000.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 11/5/2025 | Boost Price Target | $70.97 | $95.00 | Market Outperform | $00.00 00.00% ROI | |
KLRS Kalaris Therapeutics | 11/3/2025 | Initiated Coverage | $5.03 | $20.00 | Market Outperform | $0.00 00.00% ROI | |
SPRB Spruce Biosciences | 10/28/2025 | Set Price Target | $123.02 | $254.00 | Market Outperform | $00.00 00.00% ROI | |
SVRA Savara | 10/23/2025 | Boost Price Target | $4.11 | $11.00 | Market Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 10/15/2025 | Boost Price Target | $6.42 | $27.00 | Market Outperform | $0.00 00.00% ROI | |
ATXS Astria Therapeutics | 10/15/2025 | Reiterated Rating | $11.61 | | Market Perform | $0.00 00.00% ROI | |
OCUL Ocular Therapeutix | 10/1/2025 | Boost Price Target | $11.69 | $29.00 | Market Outperform | $0.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 9/26/2025 | Boost Price Target | $35.89 | $143.00 | Market Outperform | $0.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 9/25/2025 | Boost Price Target | $96.86 | $142.00 | Market Outperform | $00.00 00.00% ROI | |
KALV KalVista Pharmaceuticals | 9/12/2025 | Boost Price Target | $14.81 | $28.00 | Market Outperform | $0.00 00.00% ROI | |
MDGL Madrigal Pharmaceuticals | 8/20/2025 | Boost Price Target | $379.55 | $485.00 | Market Outperform | $000.00 00.00% ROI | |
LRMR Larimar Therapeutics | 8/15/2025 | Lower Price Target | $4.30 | $18.00 | Market Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 8/13/2025 | Lower Price Target | $21.47 | $52.00 | Market Outperform | $00.00 00.00% ROI | |
ATXS Astria Therapeutics | 8/13/2025 | Boost Price Target | $6.88 | $26.00 | Market Outperform | $0.00 00.00% ROI | |
QNCX Quince Therapeutics | 8/12/2025 | Lower Price Target | $314.00 | $1,600.00 | Market Outperform | $00.00 00.00% ROI | |
CRNX Crinetics Pharmaceuticals | 8/11/2025 | Lower Price Target | $26.85 | $86.00 | Market Outperform | $00.00 00.00% ROI | |
GPCR Structure Therapeutics | 8/7/2025 | Lower Price Target | $16.31 | $87.00 | Market Outperform | $00.00 00.00% ROI | |
The Democrats can’t stop this (Ad) Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency.
His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge.
He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century. Get Porter Stansberry's briefing on Trump's new dollar and the three steps he outlines. |
PTGX Protagonist Therapeutics | 8/7/2025 | Boost Price Target | $53.42 | $69.00 | Market Outperform | $000.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 8/7/2025 | Set Price Target | $59.41 | $81.00 | Market Outperform | $00.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 8/6/2025 | Boost Price Target | $89.85 | $135.00 | Market Outperform | $000.00 00.00% ROI | |
ALT Altimmune | 7/10/2025 | Lower Price Target | $4.21 | $15.00 | Market Outperform | $0.00 00.00% ROI | |
KALV KalVista Pharmaceuticals | 7/8/2025 | Boost Price Target | $15.69 | $27.00 | Market Outperform | $00.00 00.00% ROI | |
PRQR ProQR Therapeutics | 6/27/2025 | Reiterated Rating | $2.16 | $8.00 | Market Outperform | $0.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 6/26/2025 | Reiterated Rating | $62.19 | $84.00 | Market Outperform | $000.00 00.00% ROI | |
DBVT DBV Technologies | 6/26/2025 | Reiterated Rating | $9.06 | $21.00 | Market Outperform | $00.00 00.00% ROI | |
SKYE Skye Bioscience | 6/24/2025 | Reiterated Rating | $25.27 | $120.00 | Market Outperform | $0.00 00.00% ROI | |
GPCR Structure Therapeutics | 6/23/2025 | Reiterated Rating | $21.73 | $89.00 | Market Outperform | $00.00 00.00% ROI | |
DBVT DBV Technologies | 5/27/2025 | Boost Price Target | $8.41 | $21.00 | Market Outperform | $00.00 00.00% ROI | |
AURA Aura Biosciences | 5/23/2025 | Reiterated Rating | $5.91 | $19.00 | Market Outperform | $0.00 00.00% ROI | |
CLSD Clearside Biomedical | 5/16/2025 | Reiterated Rating | $13.23 | $75.00 | Market Outperform | $0.00 00.00% ROI | |
MIRM Mirum Pharmaceuticals | 5/9/2025 | Boost Price Target | $45.07 | $76.00 | Market Outperform | $000.00 00.00% ROI | |
MDGL Madrigal Pharmaceuticals | 4/24/2025 | Reiterated Rating | $308.00 | $443.00 | Market Outperform | $000.00 00.00% ROI | |
MBX MBX Biosciences | 4/10/2025 | Initiated Coverage | $6.12 | $38.00 | Market Outperform | $00.00 00.00% ROI | |
RLYB Rallybio | 4/8/2025 | Downgrade | $0.25 | | Hold | $0.00 00.00% ROI | |
AURA Aura Biosciences | 3/26/2025 | Set Price Target | $5.25 | $19.00 | | $0.00 00.00% ROI | |
PTGX Protagonist Therapeutics | 2/7/2025 | Reiterated Rating | $39.61 | $58.00 | Market Outperform | $00.00 00.00% ROI | |
ATXS Astria Therapeutics | 1/31/2025 | Initiated Coverage | $7.49 | $26.00 | Outperform | $00.00 00.00% ROI | |
KALV KalVista Pharmaceuticals | 1/31/2025 | Initiated Coverage | $8.77 | $19.00 | Outperform | $00.00 00.00% ROI | |
PHVS Pharvaris | 1/31/2025 | Boost Price Target | $18.06 | $55.00 | Market Outperform | $00.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 1/31/2025 | Reiterated Rating | $7.96 | $18.00 | Market Outperform | $0.00 00.00% ROI | |
ATXS Astria Therapeutics | 1/31/2025 | Upgrade | $7.86 | | Strong-Buy | $00.00 00.00% ROI | |
KALV KalVista Pharmaceuticals | 1/31/2025 | Upgrade | $8.91 | | Strong-Buy | $00.00 00.00% ROI | |
DBVT DBV Technologies | 1/10/2025 | Reiterated Rating | $4.14 | $10.00 | Market Outperform | $00.00 00.00% ROI | |
MDGL Madrigal Pharmaceuticals | 1/10/2025 | Reiterated Rating | $330.62 | $427.00 | Market Outperform | $000.00 00.00% ROI | |
RYTM Rhythm Pharmaceuticals | 12/23/2024 | Reiterated Rating | $56.12 | $75.00 | Market Outperform | $000.00 00.00% ROI | |
SPRB Spruce Biosciences | 12/11/2024 | Downgrade | $0.43 | | Hold | $00.00 00.00% ROI | |